Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:FSTX

F-star Therapeutics (FSTX) Stock Price, News & Analysis

F-star Therapeutics logo

About F-star Therapeutics Stock (NASDAQ:FSTX)

Key Stats

Today's Range
$7.12
$7.12
50-Day Range
$4.42
$7.12
52-Week Range
$2.07
$7.12
Volume
N/A
Average Volume
709,213 shs
Market Capitalization
$156.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.

Receive FSTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for F-star Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FSTX Stock News Headlines

Astria Therapeutics price target raised to $28 from $26 at Oppenheimer
Lake Street Remains a Buy on Aquestive Therapeutics (AQST)
This Bull Market Indicator called NVDA at $116
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
Bicara Therapeutics Rises 39% in Debut on Nasdaq
See More Headlines

FSTX Stock Analysis - Frequently Asked Questions

F-star Therapeutics, Inc. (NASDAQ:FSTX) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.06. The firm had revenue of $0.75 million for the quarter, compared to analysts' expectations of $7.18 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that F-star Therapeutics investors own include New Age Brands (NF), Aurora Cannabis (ACB), Trican Well Service (TCW), Meta Platforms (META), NIO (NIO), Plug Power (PLUG) and Copper Mountain Mining (CMMC).

Company Calendar

Last Earnings
11/10/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FSTX
Employees
84
Year Founded
N/A

Profitability

Net Income
$-31,280,000.00
Pretax Margin
-213.97%

Debt

Sales & Book Value

Annual Sales
$21.17 million
Book Value
$4.70 per share

Miscellaneous

Free Float
21,279,000
Market Cap
$156.50 million
Optionable
Not Optionable
Beta
0.85
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:FSTX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners